Visit our Homepage

ASH 2017 – Our personal Highlights

Dear colleague,

A large number of interesting abstracts addressing different aspects of Hodgkin Lymphoma (HL) were presented at the 2017 ASH1 Annual Meeting in Atlanta.


ECHELON-1 STUDY

The randomized ECHELON-1 trial comparing standard ABVD with the combination of brentuximab vedotin and AVD (A-AVD) in advanced-stage classical HL was controversially discussed in the plenary session.

The final analysis of this study revealed an improved modified 2-year progression-free survival (PFS) for A-AVD (82.1%) as compared to ABVD (77.2%).

However, conventional PFS was not reported and the improvement in tumor control did not translate into better overall survival. There was more neuropathy and hematological toxicity associated with A-AVD but fewer pulmonary events. Based on these results, final conclusions on the possible role of A-AVD in advanced classical HL could not be drawn and discussions will continue at ISHL11.


Combination of BRENTUXIMAB VEDOTIN and the ANTI-PD1 ANTIBODY NIVOLUMAB

In HL patients relapsing after first-line treatment, a phase I/II study evaluating the combination of brentuximab vedotin and the anti- PD1 antibody nivolumab as salvage approach prior to high-dose chemotherapy and autologous stem cell transplantation (ASCT) demonstrated high response rates.

Thus, a relevant proportion of patients might be treated without conventional chemotherapy at first relapse. It remains unclear whether the presented data already allow the use of such a strategy outside clinical studies since the follow-up is still limited.

The optimal use of targeted drugs as salvage treatment prior to high- dose chemotherapy and ASCT will therefore be one of the issues to be addressed in the session on relapsed HL at ISHL11.

We very much look forward to discussing these study results and a variety of other topics during the ISHL11.

ISHL11 will take place in Cologne, Germany, between October 27 and 29, 2018.


1Please note that ISHL11 is not affiliated with the American Society of Hematology.

Might also be interesting

Scientific Program Highlights: Biomarkers

Treatment stratification by PET/CT has improved outcome and reduced treatment toxicity in Hodgkin Lymphoma. Recently, results of the GHSG HD18 trial were presented at EHA 2017. In this study…

Read more…


Early Bird Registration

We are pleased to announce that the online registration for ISHL11 is now open! Early bird registration ends on May 31, 2018.

Register Online


Limited Hotel Capacities

Hotel rooms are allocated on a first-come, first-served basis, so we advise you to reserve early.

You can either book directly with the hotel or take advantage of the booking form you can download on our Website and send to us via info@hodgkinsymposium.org.

Please be aware that hotel capacities are limited due to parallel trade fair in Cologne.

Go to Accomodation

Organisation

Andreas Engert, MD
Symposium Chairman

Sven Borchmann, MD
Congress Secretary

Paul Bröckelmann, MD
Congress Secretary

Dennis Eichenauer, MD
Congress Secretary

German Hodgkin Study Group (GHSG)
University Hospital of Cologne
Kerpener Str. 62
D-50924 Köln

Read the corresponding E-Mail